Goldman Sachs raised the firm’s price target on Concentra (CON) to $26 from $24 and keeps a Buy rating on the shares. The company’s Q4 results were in line with consensus and the Q4 pre-announcement as patient visits declined 1.2%, but the management flagged an improvement in Employer Services visits in January and February and expects visit growth pressure to moderate throughout the year, turning slightly positive in late 2025, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CON:
- Concentra upgraded to Hold from Sell at Spin-Off Research
- Concentra price target raised to $26 from $25 at BofA
- Positive Outlook for Concentra Group Holdings: Buy Rating Reinforced by Strong Q4 Results and Strategic Acquisitions
- Concentra Group Holdings: Strong Financial Performance and Strategic Growth Initiatives Support Buy Rating
- Concentra reports Q4 EPS 17c, consensus 17c